Nozin in Preventing Respiratory Viral Infections in Patients Undergoing Stem Cell Transplant, PREV-NOSE STUDY
Status:
Recruiting
Trial end date:
2022-08-01
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects of Nozin in preventing respiratory viral
infections in patients undergoing stem cell transplant. Nozin is a non-antibiotic,
alcohol-based nasal sanitizer used in hospitals to prevent spread of bacterial infections and
may also prevent community acquired respiratory virus infection in stem cell transplant
recipients.
Phase:
Phase 1
Details
Lead Sponsor:
Fred Hutchinson Cancer Research Center
Collaborators:
Global Life Technologies Corp. National Cancer Institute (NCI)